Genomic analysis of childhood tumours; biological and therapeutic implications
4 Jul 2017
Genomic analysis of childhood tumours; biological and therapeutic implications
Proteogenomics in cancer research
Novel models to personalise cancer therapeutics
Latest in relapsed and refractory multiple myeloma
Lenalidomide with CD19 antibodies in L-MIND
Denosumab or zoledronic acid for bone disease in multiple myeloma
Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM
Triplet therapy for all comers in the CLL-BAG trial
Disruption of BAFF-BCR crosstalk in CLL
Interim analysis of the JULIET study
400mg imatinib as good as 800mg for 10 year CML survival
Carfilzomib combinations in ENDEAVOR and FORTE